Leonard Schleifer, Regeneron CEO (Andrew Harnik/AP)

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half af­ter be­com­ing the ex­per­i­men­tal treat­ment of choice for a new­ly di­ag­nosed pres­i­dent, Re­gen­eron’s an­ti­body cock­tail has re­ceived emer­gency use au­tho­riza­tion from the FDA. It will be used to treat non-hos­pi­tal­ized Covid-19 pa­tients who are at high-risk of pro­gress­ing.

Al­though the Rgen­eron drug is not the first an­ti­body treat­ment au­tho­rized by the FDA, the news comes as a sig­nif­i­cant mile­stone for a com­pa­ny and a treat­ment sci­en­tists have watched close­ly since the out­break be­gan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.